Antithrombotic therapy and clinical characteristics of patients hospitalized for nonvalvular atrial fibrillation in Galician internal medicine clinics
Main Article Content
Abstract
This was a multicenter, prospective, observational study that assessed the characteristics of patients with Nonvalvular Atrial Fibrillation (NVAF) admitted to internal medicine units in Galicia, Spain, as well as the antithrombotic treatment prescribed prior to hospital admission. Demographic characteristics, cardiovascular risk factors, polypharmacy, comorbidity, functional status and reasons for hospitalization were recorded for patients with NVAF admitted between January 2016 and January 2017. The antithrombotic treatment received by patients prior to hospital admission and the reasons for using this treatment were also analyzed. A total of 1419 patients were included (mean age 82.1 years; 50% male). The mean (standard deviation) number of chronic diseases per patient was 4.11(2.14) and the number of drugs being taken was 9.66(4.60). The mean CHA2DS2-VASc score was 3.09(1.26). NVAF-related hospitalizations accounted for 37.5% of all hospital admissions, with heart failure the most common reason for hospitalization (31.4%). Most patients (75.1%) with NVAF were on anticoagulants at the time of admission and direct oral anticoagulants accounted for 13.9% of anticoagulants. Functional status was the only factor associated with the use of anticoagulation therapy. In conclusion, patients with NVAF admitted to Galician internal medicine units are a diverse population. More than one third are hospitalized for causes related to NVAF, while one in four is not receiving the appropriate antithrombotic therapy. The data suggest that, when primary care physicians or a specialist prescribe antithrombotic therapy, the patient’s functional status is more relevant than established risk factors to their decision-making.
Downloads
Article Details
Copyright (c) 2019 Cerqueiro-González JM, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, et al. (2017) 'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace 19: 722-733. Link: http://bit.ly/2Oe9dFt
Cea-Calvo L, Redón J, Lozano JV, Fernández-Pérez C, Martí-Canales JC, et al. (2007) Prevalence of atrial fibrillation in the spanish population aged 60 years or more. The PREV-ICTUS study. Rev Esp Cardiol 60: 616-624. Link: http://bit.ly/2DbP3Fu
López Soto A, Formiga F, Bosch X, García Alegría J (2012) Prevalencia de la fibrilación auricular y factores relacionados en pacientes ancianos hospitalizados: estudio ESFINGE. Med Clin (Barc) 138: 231-237. Link: http://bit.ly/2XEZHxV
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130: 2071-2104. Link: http://bit.ly/2DbHKOm
Basu J, Avila R, Ricciardi R (2016) Hospital readmission rates in U.S. states: are readmissions higher where more patients with multiple chronic conditions cluster? Health Serv Res 51: 1135-1151. Link: http://bit.ly/2OaP2rR
Lip GY, Lane DA (2015) Stroke prevention in atrial fibrillation: a systematic review. JAMA 313: 1950-1962. Link: http://bit.ly/35vWJPh
Salamanca-Bautista P, Conde-Martel A, Aramburu-Bodas O, Formiga F, Trullas JC, et al. (2016) Precipitating factors of heart failure admission: Differences related to age and left ventricular ejection fraction. Int J Cardiol 219: 150-155. Link: http://bit.ly/2rf4ZEv
Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC (2011) The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 13: 1375-1385. Link: http://bit.ly/2D7Ydmm
Montes-Santiago J, Rodil V, Formiga F, Cepeda JM, Urrutia A (2013) Características y costes de los pacientes ingresados por arritmias cardiacas en España. Rev Clin Esp 213: 235-239. Link: http://bit.ly/35r2sWs
Gullón A, Suárez C, Díez-Manglano J, Formiga F, Cepeda JM, et al. (2017) Características y tratamiento antitrombótico de los pacientes ancianos con fibrilación auricular no valvular hospitalizados en Medicina Interna. Registro NONAVASC. Med Clin (Barc) 148: 204-210. Link: http://bit.ly/2OdQxp3
Iñiguez Vázquez I, Monte Secades R, Matesanz Fernández M, Romay Lema EM, et al. (2017) Characteristics and temporal pattern of readmissions of patients with atrial fibrillation hospitalized in medical departments. Rev Clin Esp 217: 309-314. Link: http://bit.ly/37xQ4pg
Mostaza J, Campo-Alonso M, Suárez C, Sánchez D, Manzano L, Cepeda J, et al. (2016) Estudio PERFILAR. Estudio para determinar el perfil y manejo del tratamiento antitrombótico de los pacientes con fibrilación auricular no valvular que acuden a los servicios de medicina interna de los hospitales españoles (EA-075). Rev Clin Esp (Espec Congr) 144
Matesanz Fernández M, Iniguez-Vázquez I, Rubal Bran D, Pértega-Díaz S, Conde Friere J, et al. (2012) Multimorbilidad en los servicios médicos hospitalarios: un problema clínico y de gestión. Galicia Clin 73: S15-S19 . Link: http://bit.ly/2DbIeEa
Matesanz-Fernandez M, Monte-Secades R, Iniguez-Vazquez I, Rubal-Bran D, Guerrero-Sande H, et al. (2015) Characteristics and temporal pattern of the readmissions of patients with multiple hospital admissions in the medical departments of a general hospital. Eur J Intern Med 26: 776-781. Link: http://bit.ly/2QK835W
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137: 263-272. Link: http://bit.ly/34jZlj6
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, et al. (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: 1093-1100. Link: http://bit.ly/2QIQ1kE
Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. A simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. Md State Med J 14: 61-65 . Link: http://bit.ly/33fZx1g
World Heath Organisation (2018) Enfermedades crónicas. Link: http://bit.ly/2sbcbSr
Schafer I, Hansen H, Schon G, Maier W, Hofels S, et al. (2009) The German MultiCare-study: patterns of multimorbidity in primary health care - protocol of a prospective cohort study. BMC Health Serv Res 9: 145. Link: http://bit.ly/2qCXMOs
Barrios V, Calderón A, Escobar C, de la Figuera M (2012) Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol 65: 47-53. Link: http://bit.ly/37s4lUN
Barrios V, Escobar C, Prieto L, Osorio G, Polo J, et al. (2015) Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Rev Esp Cardiol 68: 769-776. Link: http://bit.ly/2XJceAv
Cinza-Sanjurjo S, Rey-Aldana D, Gestal-Pereira E, Calvo-Gómez C (2015) Assessment of degree of anticoagulation control in patients with atrial fibrillation in primary health care in Galicia, Spain: ANFAGAL study. Rev Esp Cardiol 68: 753-760. Link: http://bit.ly/2rgLyuQ
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992. Link: http://bit.ly/2Daah6O
Mun JH, Chung H, Chung WH, Oh M, Jeong YM, et al. (2015) Construction of a reference genetic map of Raphanus sativus based on genotyping by whole-genome resequencing. Theor Appl Genet 128: 259-272. Link: http://bit.ly/2KN9xJ4
Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. (2017) International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 194: 132-140. Link: http://bit.ly/2OahgCW
Spence JD (2018) Cardioembolic stroke: everything has changed. Stroke Vasc Neurol 3: 76-83. Link: http://bit.ly/35t6ugS